Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Apr;10(4):1711–1722. doi: 10.21037/tau-20-1411

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

2021 Translational Andrology and Urology. All rights reserved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0.

PMC Copyright notice

METTL3 promotes resistance to cisplatin by enhancing autophagy. (A) LC3-II/GAPDH ratio and Beclin1 levels were determined by western blot analysis after overexpression or knockdown of METTL3 in TCam-2 cells. GAPDH served as the internal control. (B) Immunofluorescence of LC3-II was performed in TCam-2 cell line with different METTL3 expression. The red signal represents the LC3-II levels. (magnification, 400×). (C) Cell viability after 72 h treatment with IC25 concentration of CDDP. The METTL3-overexpressing TCam-2 cell were treated with or without autophagy inhibitor 3-MA. The data are shown as the means ± S.D. *, P<0.05; **, P<0.01; ***, P<0.001. 3-MA, 3-methyladenine; S.D., standard deviation; CDDP, cis-diamminedichloroplatinum II.